Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Shares Sold by Mutual of America Capital Management LLC

Mutual of America Capital Management LLC reduced its position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 7.2% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 92,802 shares of the specialty pharmaceutical company’s stock after selling 7,173 shares during the quarter. Mutual of America Capital Management LLC’s holdings in Collegium Pharmaceutical were worth $3,603,000 at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. Principal Securities Inc. acquired a new stake in shares of Collegium Pharmaceutical during the fourth quarter worth $40,000. China Universal Asset Management Co. Ltd. lifted its holdings in Collegium Pharmaceutical by 320.0% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 3,776 shares of the specialty pharmaceutical company’s stock valued at $116,000 after acquiring an additional 2,877 shares during the period. Assetmark Inc. lifted its holdings in Collegium Pharmaceutical by 25.5% in the fourth quarter. Assetmark Inc. now owns 5,445 shares of the specialty pharmaceutical company’s stock valued at $168,000 after acquiring an additional 1,108 shares during the period. Meritage Portfolio Management acquired a new stake in Collegium Pharmaceutical in the first quarter valued at $316,000. Finally, Johnson Investment Counsel Inc. acquired a new stake in Collegium Pharmaceutical in the fourth quarter valued at $257,000.

Collegium Pharmaceutical Trading Up 1.5 %

Collegium Pharmaceutical stock opened at $31.88 on Friday. The stock has a market cap of $1.04 billion, a PE ratio of 13.28 and a beta of 0.93. The stock has a 50-day moving average price of $33.04 and a 200 day moving average price of $34.45. Collegium Pharmaceutical, Inc. has a 52 week low of $20.95 and a 52 week high of $40.95. The company has a current ratio of 1.21, a quick ratio of 1.14 and a debt-to-equity ratio of 1.98.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its quarterly earnings data on Thursday, May 9th. The specialty pharmaceutical company reported $1.32 EPS for the quarter, missing analysts’ consensus estimates of $1.36 by ($0.04). The company had revenue of $144.92 million for the quarter, compared to analysts’ expectations of $147.04 million. Collegium Pharmaceutical had a return on equity of 104.98% and a net margin of 16.46%. Equities research analysts predict that Collegium Pharmaceutical, Inc. will post 5.57 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, EVP Scott Dreyer sold 56,807 shares of Collegium Pharmaceutical stock in a transaction dated Friday, May 24th. The stock was sold at an average price of $33.98, for a total transaction of $1,930,301.86. Following the completion of the sale, the executive vice president now owns 105,902 shares in the company, valued at approximately $3,598,549.96. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In other Collegium Pharmaceutical news, CFO Colleen Tupper sold 19,710 shares of the firm’s stock in a transaction dated Tuesday, May 28th. The stock was sold at an average price of $34.21, for a total value of $674,279.10. Following the sale, the chief financial officer now directly owns 130,845 shares of the company’s stock, valued at approximately $4,476,207.45. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Scott Dreyer sold 56,807 shares of the firm’s stock in a transaction dated Friday, May 24th. The stock was sold at an average price of $33.98, for a total value of $1,930,301.86. Following the completion of the sale, the executive vice president now directly owns 105,902 shares in the company, valued at $3,598,549.96. The disclosure for this sale can be found here. In the last quarter, insiders sold 105,502 shares of company stock worth $3,540,796. 3.98% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of equities research analysts have commented on COLL shares. Piper Sandler downgraded Collegium Pharmaceutical from an “overweight” rating to a “neutral” rating and set a $39.00 target price for the company. in a report on Friday, May 10th. Jefferies Financial Group upgraded Collegium Pharmaceutical from a “hold” rating to a “buy” rating and raised their price target for the company from $41.00 to $44.00 in a research report on Friday, June 7th. StockNews.com cut Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, May 1st. Finally, Needham & Company LLC cut Collegium Pharmaceutical from a “buy” rating to a “hold” rating in a research report on Friday, May 10th. Three investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $40.75.

Collegium Pharmaceutical Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.